Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562 by Sargent, J M et al.
Despite major advances in drug development, support therapy and
adjuvant treatment, overall survival in advanced breast cancer
continues to be discouragingly low. Drug resistance remains one
of the major problems in this disease. Development of the
multidrug resistance (MDR) phenotype is particularly challenging
because tumours become cross-resistant to multiple, chemically
unrelated cytotoxic agents. Expression of the MDR1 gene, charac-
terized by the presence of the 170 kD transmembrane transporter
P-glycoprotein (Pgp), is often low prior to treatment but is
frequently increased during the progression of disease and most
notably after chemotherapy (Chaudhary and Roninson, 1993).
Indeed, increased Pgp expression has been repeatedly observed in
samples from patients with breast cancer (Trock et al, 1997).
Conventional approaches to overcoming this resistance have
involved the concomitant administration of resistance modulators,
usually as second line therapy. These agents include the more
potent second generation analogues such as SDZ PSC 833 (PSC
833) which is capable of circumventing MDR (Advani et al,
1999). Clinical trials utilizing these agents have, however, been
disappointing particularly in solid tumours (Kaye, 1999) and a
novel approach to the problem may be required. Instead of treating
resistance after it has occurred, perhaps it may be more pertinent to
attempt to prevent its emergence right from the onset of treatment.
There is clinical evidence to suggest that the chelating agent,
dexrazoxane (DXRz) may have this effect. 
Dexrazoxane protects against the cardiotoxicity of doxorubicin
and when combined with the FAC regime (5-fluorouricil, doxoru-
bicin and cyclophosphamide) not only leads to a significant
decrease in cardiotoxicity but also to a substantial increase in
overall median survival time for patients with advanced breast
cancer responsive to FAC (Swain et al, 1997). This survival advan-
tage could be explained by a reduction in the emergence of MDR
since dexrazoxane has been reported to inhibit topoisomerase II
and to potentiate the efficacy of a number of antitumour agents
(Hasinoff et al, 1998) in addition to its cardioprotective effect. At
present, any common factor connecting these events remains specu-
lative. 
The aim of this in-vitro study was to attempt to mimic the clin-
ical observation that the combination of dexrazoxane with doxoru-
bicin leads to increased efficacy, with particular interest in the
development of drug resistance. Doxorubicin resistance was
induced in the presence and absence of clinically achievable levels
of dexrazoxane in the human cell line, K562. The K562 line was
chosen, as it is a robust model which develops an MDR1 pheno-
type after a relatively short period of exposure to doxorubicin
(Kato et al, 1990). The expression and function of P-glycoprotein
was measured along with cellular sensitivity in order to assess
emerging MDR1 in the resultant sublines. 
MATERIALS AND METHODS 
Cell lines 
K562 is a human leukaemia cell line that was derived from a
patient with chronic myeloid leukaemia in blast cell crisis. By
stepwise increasing the concentration of doxorubicin, this cell line
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1990). K562 cells have a doubling time of approximately 16
hours, were maintained in RPMI 1640 culture medium plus 10%
FCS, 100 1U ml–1 penicillin, 100 mg ml–1 streptomycin (all from
Sigma Aldridge, UK) and were passaged every 48 hours to 
1.0  ´ 105 cells ml–1. 
A pilot study was carried out in order to optimize the concentra-
tions for long-term exposure to dexrazoxane (Cardioxane, Chiron,
UK) and doxorubicin. We tested dexrazoxane at a range of
concentrations up to 5 mM and established that concentrations 
up to 200 nM were commensurate with long-term growth.
Doxorubicin resistant sublines were then generated by incubating
K562 parental cells at 1.0 ´ 105 cells ml–1 in the presence of
sublethal concentrations of doxorubicin ± dexrazoxane. The
starting concentration used for doxorubicin was 10 nM and it was
possible to increase this stepwise by 10 nM amounts to 40 nM in
the presence of 20 nM dexrazoxane. Cells selected in doxorubicin
without dexrazoxane showed typical signs of drug damage mani-
fested by cell swelling, alterations in cell shape and granularity.
This became detectable after 4 days and when the cells had
adapted to this environment (approximately 2–4 weeks) the
concentration of doxorubicin was increased. The cells were exam-
ined microscopically every 48 hours before passaging and if low
growth and/or increasing background debris were seen, cells were
maintained in the same drug concentration for a further week.
Preliminary results of this pilot study were extremely encouraging
and suggested a significant impairment of the MDR1 phenotype in
cells selected in doxorubicin + dexrazoxane. 
A further experiment was carried out using the optimum
concentrations of dexrazoxane and doxorubicin established in the
pilot study. In this experiment, cells were selected in increasing
concentrations of doxorubicin up to 30 nM ± 20 nM dexrazoxane.
Cells selected in 15 and 20 nM (K562DOX15, K562DOX20) were
frozen in liquid nitrogen in RPMI 1640 plus 20% FCS and 10%
DMSO to enable batch testing for cytotoxicity and MDR markers
alongside cells selected in 30 nM doxorubicin (K562DOX30).
K562 parental cells, the MDR-positive K562DOX100 subline
maintained in 100 nM doxorubicin and cells grown in dexra-
zoxane alone at the above concentrations were included as
controls. 
Cytotoxicity studies 
The doxorubicin cytotoxicity of each of the resultant sublines
grown in the presence and absence of dexrazoxane was measured
on 2 separate occasions. Cells from all sublines were continually
exposed to 8 concentrations (0.2–10 mM) of doxorubicin for 48 h
at 37˚C, 5% CO2. Cells incubated in culture medium without drug,
served as controls. The MTT assay was used to assess cell survival
after drug exposure (Sargent and Taylor, 1989) and the IC50
(concentration of drug causing 50% growth inhibition) was calcu-
lated for each experiment. 
Doxorubicin cytotoxicity was also measured in the presence (at
a fixed concentration of 2 mM) of the MDR modulator PSC 833
(gift from Novartis, UK). A sensitization ratio of the IC50 for
doxorubicin over IC50 for doxorubicin + PSC 833 gave a measure
of modulation effect. 
In order to test whether dexrazoxane acts as an MDR modulator in
the short term, K562 cells and K562DOX15,30 and 100 sublines were
exposed to doxorubicin as above ± dexrazoxane at 20 nM or 4 mM
(non-toxic concentration) for 48 hours. Cells from each sub-line
exposed to dexrazoxane at the appropriate concentration were used
as controls. Sensitization ratios were calculated as above. 
MDR1 gene expression 
RT-PCR was used to determine MDR1 gene expression in all
sublines. The single step method used for isolation of RNA was
based on that of Chomczynski and Sacchi (1987) using Triazol
reagent (Life Technologies, UK). Total RNA was reverse tran-
scribed using Superscript II (Life Technologies, UK) and random
hexanucleotides (Pharmacia), according to manufacturers’ instruc-
tions. PCR was performed on cDNA as described by Yanagisawa
et al (1999). The sequences of the MDR1 primers (Oswel DNA
Services, Southampton, UK) were as previously reported (Bordow
et al, 1994). A 3 min initial denaturation step at 94˚C was followed
by 30 cycles of 45 s at 94˚C, 45 s at 55˚C and 90 s at 72˚C ending
with 10 min at 72˚C (Touchdown Thermocycler, Hybaid, UK). An
RNA free negative control was run and b2-microglobulin was used
as an internal control for DNA loading. PCR products were visual-
ized after gel electrophoresis (1% agarose) by UV translumination
using ethidium bromide staining. Results were recorded using a
Gelcam Polaroid camera (Helena Biosciences, UK). 
P-glycoprotein expression 
The P-glycoprotein expression of all cell lines was measured by
flow cytometry with the MRK 16 antibody (TCS Biologicals,
UK). Indirect immunofluorescence was carried out utilizing a
FITC-labelled goat anti-mouse secondary antibody (Beckman
Coulter, UK). An isotype matched control (IgG2a, Sigma Aldrich,
UK) was run with every test at the same IgG concentration as the
test antibody to measure any non-specific binding. Cells (0.5–2 ´106)
were incubated in MRK 16 (5 mg ml–1) for 1 h at room tempera-
ture. After washing ´ 2, the FITC-labelled secondary antibody was
added to all tubes and allowed to react for 45 min at room temper-
ature in the dark. After washing ´ 2, cells were kept on ice until
analysed using a Coulter Epics XL flow cytometer equipped with
an argon laser with an excitation wavelength of 488 nm. Results
were expressed as the ratio of the mean fluorescence associated
with the test over that for the control. Therefore, results >1.0 indi-
cate the presence of P-glycoprotein. 
Drug accumulation 
Using flow cytometry, the accumulation of daunorubicin
(Cerubidin, Rhone-Poulenc Rorer, UK) was measured in the pres-
ence and absence of the MDR-modulating agent PSC 833 to indi-
cate the presence of functional P-glycoprotein. Daunorubicin, an
analogue of doxorubicin, was used because it is a good substrate
for P-glycoprotein and we have previous experience of under-
taking functional analysis of P-glycoprotein using this method-
ology (Elgie et al, 1999). Cells (5 ´ 105) from all lines were
incubated with and without PSC 833 (2 mM) for 1 hour at 37˚C,
5% CO2. Daunorubicin (5 mM) was added throughout for a further
hour incubation. Cells were then washed ´ 2 in ice cold PBS and
kept on ice until required for flow cytometric analysis. Drug accu-
mulation was measured as mean fluorescence units (MFUs). 
Statistics 
The effect of dexrazoxane on the generation of resistance to
doxorubicin, the ability of dexrazoxane or PSC 833 to modulate 
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between doxorubicin in the growth medium and cellular resistance
(IC50) was analysed using the Pearson r correlation coefficient. 
RESULTS 
Doxorubicin cytotoxicity 
There was a linear relationship between increasing concentra-
tion of doxorubicin in the selecting medium (15–30 nM) and
increasing doxorubicin IC50 (r2 = 0.908). The addition of 20 nM
dexrazoxane to the selecting medium impaired this increase in IC50
(Table 1, P < 0.0001). 
When the modulating agent PSC 833 was added to the cytotoxi-
city assay, the sublines cultured in >15 nM doxorubicin showed
high sensitization ratios indicating the presence of MDR (Table 1).
Ratios obtained from cells incubated in doxorubicin + dexra-
zoxane were all ≤1.0 with no indication of MDR. Sensitization
ratios obtained from cells grown in dexrazoxane alone were not
significantly different from parental cells (P = 0.686). 
Dexrazoxane as a modulator of P-gp 
Table 2 shows that there was no significant increase in doxorubicin
sensitivity after 48 hour co-incubation of K562DOX30 or
K562DOX100 cells with dexrazoxane either at 20 nM or 4 mM, a
concentration found non-toxic after short-term exposure. These
results suggest that dexrazoxane does not overcome MDR once
present. 
Growth characteristics and appearance of sublines 
Poor growth was seen for cells incubated in doxorubicin + dexra-
zoxane. On microscopic examination, many apoptotic changes
could be noted with nuclear fragmentation, blebbing and a marked
variation in cell size from cell fragments to large swollen cells.
These cells remained sensitive to doxorubicin but were being
cultured in sublethal concentrations of doxorubicin, approximately
a tenth of IC50. The appearance of cells selected in doxorubicin
alone, however, recovered within 2 weeks, when they closely
resembled the parental cells. Cells grown in dexrazoxane alone
always seemed healthy and appeared no different from the parental
cells having the same doxorubicin sensitivity as the parental line
and lacking the MDR1 phenotype. 
MDR1 gene expression 
Figure 1 shows that MDR1 mRNA was increased when the
doxorubicin concentration in the selecting medium was >15 nM.
In the presence of dexrazoxane, this increase in gene expres-
sion was abolished in cells selected in 20 nM doxorubicin
(K562DOX20) and markedly reduced in cells selected in 30 nM
(K562DOX30) doxorubicin. The b2-microglobulin results con-
firmed that RNA levels were comparable throughout all lines. 
P-glycoprotein expression 
The P-glycoprotein expression of the sublines is shown in Figure 2.
Without dexrazoxane, P-glycoprotein appears to quickly reach
maximal expression after selection in >15 nM doxorubicin. The
addition of dexrazoxane to the selecting medium prevented the
expression of P-glycoprotein (P < 0.001) for several months. 
Drug accumulation ± PSC 833 
Drug accumulation was assessed after incubating cells from all
lines in daunorubicin. Culture of cells in >15 nM doxorubicin
significantly reduced intracellular daunorubicin content. Con-
comitant addition of dexrazoxane to the selecting medium
Dexrazoxane impairs emergence of doxorubicin resistance 961
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Table 1 Effect of selection in doxorubicin ± dexrazoxane on doxorubicin IC50, and modulation by PSC 833 
DOX in selecting 
Dox IC50 (mM) Sensitization ratio (DOX IC50/DOX+PSC IC50) 
medium (nM) –DXRz +DXRz –DXRz +DXRz 
0 0.22 ± 0.06 0.34 ± 0.06 0.51 ± 0.16 0.63 ± 0.2 
15 0.38 ± 0.14 0.5 ± 0.1 0.76 ± 0.31 0.98 ± 0.15 
20 5.31 ± 1.06 0.34 ± 0.0 9.35 ± 1.87 0.68 ± 0.09 
P = 0.04 P = 0.044 
30 8.57 ± 0.03 0.58 ± 0.25 12.17 ± 0.34 0.93 ± 0.19 
P < 0.0001 P = 0.001 
100 7.83 ± 0.43 nta 14.91 ± 0.08 nt 
ant = not tested. Results expressed as mean of 2 separate experiments ± SE. 
Table 2 Dexrazoxane does not modulate P-glycoprotein in the short term 
DOX in selecting  DOX lC50 DOX + DXRz (20 nM)  DOX + DXRz (4 mM)  
medium (nM) (mM) IC50 (mM) IC50 (mM)
0 0.42 ± 0.04 0.37 ± 0.08 0.41 ± 0.17 
15 0.59 ± 0.1 0.49 ± 0.03 0.58 ± 0.08 
30 7.07 ± 1.05 6.72 ± 2.42 6.37 ± 1.21 
100 8.52 ± 2.67 8.15 ± 2.18 9.29 ± 2.41 
Results expressed as mean of 2 separate experiments ± SE. abolished this reduction (Figure 3A) (P < 0.001). The intracellular
daunorubicin content was also measured in the presence of the
MDR modulator PSC 833 to give a measure of functional P-glyco-
protein. Results shown in Figure 3B suggest that the reduction in
daunorubicin content found in cells selected in doxorubicin >15 nM
was MDR related as PSC 833 completely inhibited this effect. 
Time course of induction of MDR1 phenotype 
K562DOX30 cells were cultured in 30 nM doxorubicin 6dexra-
zoxane for a period of several months (Figure 4). After approxi-
mately 5 months, weak expression of the MDR1 gene was seen for
cells selected in both agents (Fig. 1). This was soon followed by
an increase in P-gp expression which reached a peak around 8
months. The increased P-gp expression was accompanied by an
attendant fall in intracellular drug accumulation and eventually by
a steep rise in doxorubicin IC50. 
DISCUSSION 
The clinical observation of increased survival in breast cancer
patients treated with the FAC regime plus the cardioprotectant
dexrazoxane is particularly interesting because this difference in
survival remained even when patients were censored on a cardiac
event (Swain et al, 1997). This suggests that this beneficial effect
was caused by something other than cardioprotection. It is unlikely
to be higher dose chemotherapy due to reduced toxicity since the
survival benefit of dose-intensive therapy has yet to be shown in
breast cancer (Weiss, 1999). It is possible, therefore, that dexra-
zoxane is impairing the emergence of drug resistance and the
results of our study support this theory. We found that dexrazoxane
significantly delayed the induction of MDR1 in the K562 human
cell line for several months. The effect was repeatable as our initial
pilot study showed similar results. In addition, the ratio of dexra-
zoxane to doxorubicin commonly given for cardioprotection is
10:1. We have found, however, that dexrazoxane significantly
prevents MDR at a ratio of 1:1. 
If dexrazoxane already with proven effect as a cardioprotectant,
also has the added effect of preventing or delaying the emergence
of drug resistance as our results suggest, it then becomes an indis-
pensable part of the cytotoxic armoury. Very few studies have
addressed the approach of resistance prevention, most being
concerned with resistance reversal. Sikic et al (1997) have shown
that the MDR modulator PSC 833 can decrease the mutation rate
for resistance to doxorubicin by suppressing the activation of the
MDR1 gene and the appearance of MDR mutants. Our findings 
of reduced MDR1 expression in sublines grown in the presence 
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Figure 1 MDR1 gene expression in K562 sublines after selection in
doxorubicin (DOX) ± dexrazoxane (DXRz, top panel), b2 microglobulin
controls (bottom panel) 
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Figure 2 P-glycoprotein expression of cells selected in increasing
concentrations of doxorubicin in the presence (triangles and thick line) and
absence (squares and thin line) of 20 nM dexrazoxane, P < 0.001. Results
were expressed as the ratio of the mean fluorescence associated with cells
stained with MRK 16 over that for cells stained with an isotype matched
control. Data points represent the mean of 2 separate experiments ± SE 
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Figure 3 (A) Intracellular daunorubicin concentration of cells selected in increasing concentrations of doxorubicin in the presence (black columns) and
absence (white columns) of 20 nM dexrazoxane, P < 0.001. (B) Effect of concomitant incubation in PSC 833 on intracellular daunorubicin concentration. Results
were expressed as mean fluorescence units after incubation in 5 mM daunorubicin. Columns represent the mean of 2 separate experiments ± SE of both doxorubicin and dexrazoxane support this theory.
Interestingly, to our knowledge, dexrazoxane has not been
described as a modulator of MDR. Further investigating this pos-
sibility, we did not find any increase in doxorubicin sensitivity on
short-term co-incubation with dexrazoxane in the chemosensi-
tivity assay. Thus it appears that the positive effect of dexrazoxane
is confined to the emergence of resistance rather than its circum-
vention. As dexrazoxane is known to cause cell cycle arrest at
G2/M (Sharpe et al, 1970; Scambia et al, 1995), it is possible that
by slowing down the growth rate of these sublines, dexrazoxane is
delaying mutation to the resistant phenotype. 
PKC inhibitors such as staurosporine have been shown to block
MDR1 induction by cytotoxic drugs (Chaudhary and Roninson,
1993). PKC-mediated transcriptional stimulation is thought to be
exerted through the interaction of the Jun and Fos proteins with the
AP-1 promoter element. A form of the AP-1 element is found in
the major promotor of the human MDR1 gene. Perhaps dexra-
zoxane also causes inhibition of PKC therefore blocking transcrip-
tion of the MDR1 gene. Recently Lucci et al (1999) reported that
MDR modulators block the conversion of ceramide to glucosylce-
ramide in MDR cells. Because ceramide is a critical component of
the apoptosis-signalling cascade, this enhances cytotoxicity. It is
possible that dexrazoxane can also affect cellular ceramide levels
in cells exposed to MDR-related agents. These theories require
further investigation. 
K562 cells grown in doxorubicin + dexrazoxane may exhibit
resistance caused by a mechanism other than overexpression of the
MDR1 gene hence the lack of functional P-glycoprotein. A similar
study by Futscher et al (1996) using the human multiple myeloma
cell line, RPMI 8226 (8226/S) demonstrated that cells selected by
growth in doxorubicin alone exhibited the classical MDR pheno-
type mediated by the MDR1 gene. However, drug resistance seen
in doxorubicin + verapamil selected cells was mediated through
decreases in topoisomerase II protein levels and catalytic activity
and not by P-glycoprotein overexpression. The presence of
another mechanism of resistance after growth in doxorubicin 
+ dexrazoxane seems unlikely as we were unable to demonstrate any
significant increase in doxorubicin IC50 until after approximately 
7 months continuous exposure to these agents in combination. 
The question arises whether continuous exposure to low doses
of these agents is clinically relevant, as conventional treatment
with this combination commonly involves pulsed therapy every
3–4 weeks. Perhaps a more realistic experiment would be to mimic
this pulsed therapy. Chaudhary and Roninson (1993), however,
reported that MDR1 expression and associated resistance can
continue for several weeks after the removal of the drug,
suggesting that continuous exposure at low dose may be a reason-
able model to test. Indeed, the delay in emergence of resistance
seen in our model could translate into a considerable length of time
in vivo with the pulsed therapy given in the clinic. 
The original clinical observation of increased survival after
therapy containing doxorubicin and dexrazoxane was made in
breast cancer patients suggesting it would be very worthwhile
repeating this in vitro study in the MCF7 human breast cancer cell
line in the future. One of the reasons we used a leukaemia cell line
for our study was because, in our experience, it is relatively easy to
induce doxorubicin resistance in the K562 line to create an MDR-
positive subline and we have previously used K562DOX100 to
control drug resistance experiments (Elgie et al, 1999). The other
reason was that dexrazoxane has a proven effect in AML blasts,
being cytotoxic after prolonged exposure (Pearlman et al, 1997).
This group also showed that dexrazoxane does not abrogate the
doxorubicin sensitivity of AML blasts in vitro. Indeed, dexra-
zoxane can potentiate the activity of other drugs, for example,
topotecan in K562 cells (Synold et al, 1997) and also cisplatin in
human ovarian cancer (Scambia et al, 1995). Lemez and Maresova
(1998) found that 5 relapsed or refractory AML patients subse-
quently treated with daunorubicin + dexrazoxane all went into
remission. Synold et al (1998) found that steady-state dexrazoxane
plasma concentrations of 4 mM can be achieved safely and that
prolonged exposure to dexrazoxane at this level is cytotoxic to
human leukaemia cells in vitro. We did not find dexrazoxane to be
cytotoxic at the nanomolar concentrations used in our study and
there were no differences detected in the K562 sublines grown in
dexrazoxane when compared to the parental line. 
This is the first report of the ability of dexrazoxane to impair the
emergence of drug resistance and these results may help to explain
the observed increased median survival time found in responding
breast cancer treated with FAC plus dexrazoxane. Anthracyclines
are one of the most widely used groups of agents in chemotherapy
and show significant efficacy in both haematological and solid
tumours. Our observations suggest that the routine use of dexra-
zoxane in combination with anthracyclines may delay the onset of
classical multidrug resistance, the major mechanism of resistance
associated with these drugs. This would therefore enable patients
who initially responded to their therapy to continue to respond
Dexrazoxane impairs emergence of doxorubicin resistance 963
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Figure 4 Time course showing a significant delay in the emergence of the
MDR1 phenotype in K562 cells after incubation in doxorubicin + dexrazoxane
(rectangles) compared to doxorubicin alone (diamonds). Top panel: 
P-glycoprotein expression (ratio test/control); middle panel: drug
accumulation (MFUs); bottom panel: doxorubicin IC50without the development of the most common obstacle to treat-
ment failure. The clinical implications therefore, are immense and
suggest that anthracycline-sensitive tumours should be treated
with dexrazoxane ab initio if maximum benefit of the combination
is to be obtained. 
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